Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2f70fbcb50a577c8d40360fb9d9c1ad8 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6031 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-572 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4713 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0639 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70539 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-385 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-646 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02 |
filingDate |
2020-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9077dc66cd53ab0d6c36c4379e4085e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e801d2a2757e9206355b43609daa81f5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_26645385f100e104a06360bed9882c10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0af634a4bb869422e4c179bf09d0682c |
publicationDate |
2020-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
JP-2020079271-A |
titleOfInvention |
Novel immunogenic peptide |
abstract |
PROBLEM TO BE SOLVED: To provide a pharmaceutically active peptide for immunogenic peptides, which gives rise to antigen-specific cytolytic CD4+ T cells and is for various disorders including autoimmune diseases such as multiple sclerosis. .. SOLUTION: HX(0,2)-CX(2)-[CST] or [CST]- is directly contacted with the MHC class II T cell epitope of the antigen or separated from the epitope by a maximum of 7 amino acids. An isolated immunogenic peptide of 13 to 100 amino acids containing a redox motif having a specific sequence of X(2)-CX(0,2)-H. [Selection diagram] Figure 1 |
priorityDate |
2014-10-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |